Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelopes. The Company has over a decade of experience in optimizing membrane proteins, enabling the isolation, characterization, and engineering of monoclonal antibodies against otherwise intractable membrane protein targets. Integral Molecular has worked with over 100 different partners and customers, including all of the top 10 pharmaceutical companies.

Integral membrane proteins include some of the most important therapeutic targets. Yet these types of proteins are very difficult to study due to their structural complexity and inability to be removed from the lipid membrane in conformationally-intact states. At Integral Molecular, we develop innovative technologies and products that address these demanding yet important targets.

Founded in 2001, Integral Molecular holds intellectual property rights covering all aspects of its technologies, including core patents licensed exclusively from the University of Pennsylvania.